prnasiaDecember 16, 2019
Tag: Ally Bridge Group , Financings , Three New Medtech Investments
Ally Bridge Group ("ABG"), a leading global life science investment group, has announced that it recently led investments in three new medical technology companies. Each of the three companies is a commercial-stage, leading innovator re-setting the standard of care in its respective category. They include:
"Medtech, as with biotech, remains a must-invest sector for ABG, where we focus on best-in-class technologies to disrupt current standards of care," said Frank Yu, CEO and CIO of Ally Bridge Group. "The closing of these investments brings the aggregate amount of ABG-led private life science investments to above $500 mm over the last 18 months, which include ABG's lead role in investments in Grail (early cancer detection), Pulmonx (interventional pulmonology), Quantum Surgical (interventional oncology). All of these companies, with the exceptions of one in Israel and one in France, are based in Silicon Valley, California, USA."
"Our active investments that leverage powerful synergies across private and public markets, coupled with our M&A knowhow and cross-border value-add, position ABG uniquely as a leading investor in late-stage best-in-class life science technologies", adds Yu.
About Ally Bridge Group
Ally Bridge Group ("ABG"), founded and led by Frank Yu (previously at Goldman Sachs and Och-Ziff Capital) and based in Hong Kong, S.A.R., China and New York, is a global life science-focused investment firm. ABG manages over US$2 billion in life science assets, both private and public, in the U.S., China, and Europe, from medtech to biopharmaceuticals. ABG focuses on investing in the world's most innovative medicines and leading high-impact transactions. In 2015, ABG initiated and led the landmark US$3.3 billion NYSE take-private of Wuxi Pharmatech. Over the past 18 months, ABG led over US$500 million private investments in industry-leading life science companies. ABG has expertise in cementing strategic partnerships between emerging life science companies and industry leaders, and across different geographies.
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the reproduced articles,
please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: